Chemocentryx Inc (CCXI) investors sentiment decreased to 0.93 in 2018 Q4. It’s down -0.05, from 0.98 in 2018Q3. The ratio has worsened, as 42 funds opened new or increased stock positions, while 45 sold and reduced equity positions in Chemocentryx Inc. The funds in our database now possess: 27.13 million shares, up from 26.80 million shares in 2018Q3. Also, the number of funds holding Chemocentryx Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 38 Increased: 24 New Position: 18.
TPG Specialty Lending, Inc. (TSLX) formed double top with $21.17 target or 5.00% above today’s $20.16 share price. TPG Specialty Lending, Inc. (TSLX) has $1.32 billion valuation. The stock decreased 0.40% or $0.08 during the last trading session, reaching $20.16. About 447,553 shares traded or 60.40% up from the average. TPG Specialty Lending, Inc. (NYSE:TSLX) has risen 12.44% since May 4, 2018 and is uptrending. It has outperformed by 8.07% the S&P500. Some Historical TSLX News: 19/03/2018 – TPG SPECIALTY LENDING, INC. – 40-17G; 05/03/2018 – FITCH AFFIRMS TPG SPECIALTY LENDING AT ‘BBB-‘; OUTLOOK POSITIVE; 20/03/2018 – TPG Specialty Lending, Inc. Announces Public Offering of Common Stk; 03/05/2018 – TPG Specialty Lending 4Q EPS 56c; 21/03/2018 – TPG Specialty Lending, Inc. Prices Public Offering of Common Stk; 05/03/2018 Fitch Affirms TPG Specialty Lending at ‘BBB-‘; Outlook Revised to Positive; 07/05/2018 – FERRELLGAS LP – ANNOUNCED AGREEMENT WITH LENDING GROUP LED BY TPG SPECIALTY LENDING TO PROVIDE CO WITH A NEW SENIOR SECURED CREDIT FACILITY; 03/05/2018 – TPG SPECIALTY LENDING INC TSLX.N – QTR END NET ASSET VALUE PER SHARE$16.27; 03/05/2018 – CORRECT: TPG SPECIALTY LENDING 1Q ADJ EPS 56C, EST. 46C; 02/05/2018 – Wells Fargo Advisors LLC Exits TPG Specialty Lending
Bvf Inc Il holds 9.54% of its portfolio in ChemoCentryx, Inc. for 6.69 million shares. P.A.W. Capital Corp owns 50,000 shares or 0.68% of their US portfolio. Moreover, Sio Capital Management Llc has 0.67% invested in the company for 169,257 shares. The Utah-based Wasatch Advisors Inc has invested 0.34% in the stock. Nantahala Capital Management Llc, a Connecticut-based fund reported 623,338 shares.
The stock increased 1.09% or $0.14 during the last trading session, reaching $12.93. About 138,540 shares traded. ChemoCentryx, Inc. (CCXI) has risen 12.22% since May 4, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19
Since January 1, 0001, it had 0 insider purchases, and 6 selling transactions for $1.47 million activity.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.